Janus kinase inhibitors (JAKis) are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn's disease or ulcerative colitis. Since ...

People say it every day without thinking ― “two o’clock,” “six o’clock,” “eight o’clock sharp.” But what is the purpose of that little “o” and apostrophe? Is it short for something? Why do we only use ...

Bonnie Blue’s “breeding mission” saw about 400 sign-ups from men, including gay creator Jak White. “It seemed like a fun event,” White, 20, exclusively told Us Weekly on the heels of Blue, 26, ...

Please provide your email address to receive an email when new articles are posted on . Most people with alopecia are good candidates for JAK inhibitor therapy with proper counseling and monitoring.

A phase 3 rheumatoid arthritis trial of Lynk Pharmaceuticals’ JAK1 inhibitor in China has hit its primary endpoint, boosting the prospects of a candidate designed to avoid the adverse events caused by ...

There are two types of Josh O'Connor fans. 1) Everyone who became a fan after Challengers, and 2) those of us who have seen all 26 episodes of The Durrells in Corfu. All are welcome here, an adorable ...

A meta-analysis showed no significant differences between JAK inhibitor use and TNF antagonist use in terms of the risk for serious infections or malignant neoplasms in patients with immune-mediated ...

Maddie Fisher is a writer, journalist and game developer. She was born and raised on the east coast, having started working in games journalism over fifteen years ago. She tends to enjoy musical ...

A new Jak and Daxter game is in the works at God of War developer Santa Monica Studios, or so PlayStation fans hope. Based on reporting so far, there appears to be a few different games in the works ...

Minghui Pharmaceutical has secured $131 million in what the company describes as a “pre-IPO” round to fuel the potential launch of its dermatitis cream in China as well as various clinical-stage ...

Some previous studies, including the ORAL Surveillance randomized trial, have shown moderately greater cancer risks with JAK inhibitors versus TNF inhibitors. But some other analyses of real-world ...